Developmental Research Program

发展研究计划

• 批准号: 10493634
• 负责人: LAURENCE HOWARD BAKER
• 金额: $ 12.48万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-16 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10493634
• 关键词: Award; Biology; Black race; Cancer Biology; Cancer Center; Clinic; Clinical; Clinical Trials; Collaborations; Communities; Complement; Complex; Data; Department of Defense; Development; Diagnosis; Disease; Doxorubicin; Drug resistance; Dystrophin; Enrollment; Ensure; Ewings sarcoma; Faculty; Foundations; Funding; Genetic; Genomics; Goals; Grant; Hemangioendothelioma; Hispanic; Immunooncology; Investigation; Jamaica; Jamaican; Latino; Lead; Leadership; Local Therapy; Medical Faculty; Medicine; Mentors; Mentorship; Michigan; Minority; Minority Women; Molecular Target; Neoadjuvant Therapy; Pathology; Patients; Pharmaceutical Preparations; Pilot Projects; Positioning Attribute; Principal Investigator; Program Development; Program Research Project Grants; Radiation therapy; Recommendation; Regulation; Research; Research Personnel; SECTM1 gene; Science; Scientist; Therapeutic; Translational Research; Underrepresented Populations; United States National Institutes of Health; Universities; Ursidae Family; Woman; Wood material; career; career development; design; experience; improved; innovation; interest; leiomyosarcoma; man; medical schools; member; mid-career faculty; minority investigator; molecular diagnostics; novel strategies; osteosarcoma; professor; programs; recruit; sarcoma; synovial sarcoma; translational goal

Developmental Research Program (DRP): Project Summary / Abstract The Developmental Research Program (DRP) will support the efforts of the Genetics and Genomics of Leiomyosarcoma (LMS): Improved understanding of cancer biology and new approaches to diagnosis and treatment SPORE. This DRP will complement or enhance the variety and depth of sarcoma translational research, seeking to ensure continual renewal of high-quality translational scientific investigation. The DRP supports short-range studies to establish the data needed to facilitate hypothesis-driven translational projects. Although the DRP will fund established investigators, an important goal is to identify and stimulate interest in sarcoma research among groups whose current focus may be different but sufficiently and transitionally related. In addition, we seek to attract early and mid- career investigators and especially Black and Latino or Hispanic investigators. Co-directing this program will be Steven Robinson, Associate Professor of Medicine at Mayo School of Medicine. Dr. Robinson is a Jamaican born man educated in Jamaica. For the past 4 years he has been supported by career development grants to Mayo Clinic including the institutional K12 as well as the Robert Wood Johnson Foundation Amos Medical Faculty Development Program. Dr. Robinson is recent recipient of Department of Defense IDEA Award. He also leads a ETCTN clinical trial that evaluates the combination of TVEC with radiation therapy for localized sarcoma. Dr. Robinson will also participate in this SPORE by co-leading our efforts to improve diversity in patients enrolled in clinical trials as well as increasing minority faculty participation. Dr. Baker is the Co-Director of this DRP. He is the SPORE Principal Investigator. Dr. Baker has made important contributions to the treatment of sarcomas beginning with the initial identification of doxorubicin as an effective drug in sarcoma patients; the establishment of neo-adjuvant therapy strategy making osteosarcoma and Ewing sarcoma curable diseases. Dr. Baker has an outstanding record of leadership and collaboration within the sarcoma translational research field. Dr. Baker is most proud of his mentorship efforts. Now 15 Professors of Medicine claim Dr Baker as their mentor. Robinson and Baker are joined by a highly qualified committee of experienced clinician-scientists (DRP Committee) which reviews and evaluates new pilot projects as the basis of providing recommendations to the SPORE Executive Committee (Chair, Judy Garber) and the SPORE MPI, who bear the responsibility to select DRP projects appropriate for funding. The DRP Committee includes members from major cancer centers who possess expertise in key aspects of sarcoma science and therapeutics, including biology and genetics, correlative science, sarcoma pathology, molecular diagnostics, sarcoma drug resistance, immuno-oncology and statistical design and analysis. The DRP will provide the depth required to maintain innovation in this SPORE.

发展研究计划 (DRP)：项目摘要/摘要 发展研究计划（DRP）将支持遗传学和基因组学的努力 平滑肌肉瘤（LMS）：提高对癌症生物学的理解以及诊断和治疗的新方法 治疗孢子。该 DRP 将补充或增强肉瘤转化的多样性和深度 研究，力求确保高质量转化科学研究的不断更新。发展计划 支持短期研究，以建立促进假设驱动的转化项目所需的数据。 尽管 DRP 将资助已建立的调查人员，但一个重要目标是确定并激发对以下方面的兴趣： 当前重点可能不同但充分且过渡相关的群体之间的肉瘤研究。 此外，我们力求吸引早期和中期职业调查员，特别是黑人、拉丁裔或西班牙裔调查员 调查人员。梅奥大学医学副教授 Steven Robinson 将共同指导该项目 医学院。罗宾逊博士出生于牙买加，在牙买加接受教育。在过去的 4 年里，他 得到梅奥诊所职业发展补助金的支持，包括机构 K12 以及罗伯特 伍德约翰逊基金会阿莫斯医学院发展计划。罗宾逊博士最近获得了 国防部IDEA奖。他还领导了一项 ETCTN 临床试验，该试验评估了以下药物的组合： TVEC 联合放射治疗局部肉瘤。 Robinson 博士也将参与本次 SPORE，并共同领导 我们努力提高参加临床试验的患者的多样性以及增加少数族裔教师的数量 参与。 Baker 博士是该 DRP 的联合主任。他是 SPORE 首席研究员。贝克博士有 从阿霉素的初步鉴定开始，对肉瘤的治疗做出了重要贡献 作为肉瘤患者的有效药物；新辅助治疗策略的制定 骨肉瘤和尤文肉瘤可治愈的疾病。贝克博士拥有杰出的领导能力和 肉瘤转化研究领域内的合作。贝克博士对他的指导工作感到最自豪。 现在有 15 名医学教授声称贝克博士是他们的导师。 罗宾逊和贝克由经验丰富的临床医生科学家组成的高素质委员会 (DRP 委员会）审查和评估新的试点项目，作为向委员会提供建议的基础 SPORE 执行委员会（主席，Judy Garber）和 SPORE MPI，负责选择 DRP 项目适合资助。 DRP 委员会包括来自主要癌症中心的成员，他们 拥有肉瘤科学和治疗学关键方面的专业知识，包括生物学和遗传学， 相关科学、肉瘤病理学、分子诊断、肉瘤耐药性、免疫肿瘤学和 统计设计和分析。 DRP 将提供维持 SPORE 创新所需的深度。